Conclusions
The primarily automated trial design and processes for evaluating Quit Sense were feasible and enabled successful trial delivery within anticipated timeframes, cost, and participation rates. Evidence was consistent with Quit Sense leading to a higher rate of biochemically verified abstinence relative to usual care and all end-of-trial abstinence measures favored the app and represented clinically meaningful effects. Improving saliva sample response rates and sample diversity through advert targeting are two areas for improvement in a definitive trial, which is warranted by the findings from this feasibility trial.